HomeCompareNMTR vs GBDC

NMTR vs GBDC: Dividend Comparison 2026

NMTR yields 2770.08% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372900.06M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — NMTR vs GBDC

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, NMTR beats the other by $168,996,473,671,386,340.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + GBDC for your $10,000?

NMTR: 50%GBDC: 50%
100% GBDC50/50100% NMTR
Portfolio after 10yr
$106469186470.88M
Annual income
$99,409,690,411,383,870.00/yr
Blended yield
93.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

NMTR
No analyst data
Altman Z
-49.9
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
GBDC buys
0
No recent congressional trades found for NMTR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRGBDC
Forward yield2770.08%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$212938372920.91M$20.85M
Annual income after 10y$198,819,380,806,317,020.00$16,450,733.83
Total dividends collected$211957883813.74M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: NMTR vs GBDC ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$287,708$277,008.31$12,492$1,791.70+$275.2KNMTR
2$7,756,221$7,448,373.17$16,527$3,160.58+$7.74MNMTR
3$195,960,759$187,661,602.67$23,588$5,904.90+$195.94MNMTR
4$4,640,768,087$4,431,090,074.46$37,141$11,901.65+$4640.73MNMTR
5$103,038,191,206$98,072,569,353.09$66,205$26,463.38+$103038.13MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$137,452$66,612.65+$2145286.91MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$342,372$195,298.53+$41893665.76MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$1,053,292$686,954.33+$767520674.70MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$4,111,439$2,984,416.95+$13195319729.15MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$20,849,974$16,450,733.83+$212938372900.06MNMTR

NMTR vs GBDC: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this NMTR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs ONMTR vs KONMTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.